Epitope mapping of full-length glycoprotein D from HSV2 reveals a novel CD4 + CTL epitope located at the transmembrane-cytoplasmic junction (original) (raw)

Cellular Immunology, 2006

Abstract

The glycoprotein D of HSV-2 (gD2) is currently a leading candidate vaccine target for genital herpes vaccines as both cellular and humoral responses can be generated against it. However, little is known about how vaccine composition will affect T cell epitope selection. A panel of 15-mer peptides (with 11 amino acid overlap) spanning full-length gD2 was used to investigate the fine specificity of T cell responses to gD2 as well as the role of vaccine composition on epitope selection. Spleen cells from BALB/c mice (H-2d) immunized with gD2, formulated with or without AlPO4 and/or IL-12, were stimulated in vitro with overlapping gD2 peptides. Cellular responses (lymphoproliferation and IFN-γ expression) were mapped to four epitopes within the gD2 molecule: gD249–63, gD2105–119, gD2245–259, and gD2333–347. CTL analysis of these four epitopes indicated that not all of them could serve as a CTL epitope. Mice immunized with gD2 expressed from a viral vector mounted CTL responses primarily to one epitope located in the extracellular domain of gD2 (gD2245–259). More importantly, mice immunized with gD2 co-administered with IL-12 mounted CTL responses to an additional epitope located at the transmembrane-cytoplasmic junction of gD2 (gD2333–347). The location of this novel epitope emphasizes the benefit of using full-length versions of glycoproteins when designing vaccine components.

Farooq Nasar hasn't uploaded this paper.

Let Farooq know you want this paper to be uploaded.

Ask for this paper to be uploaded.